{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:44:12Z","timestamp":1791081852208,"version":"4.1.0"},"reference-count":16,"publisher":"Wiley","issue":"102","license":[{"start":{"date-parts":[[2010,4,23]],"date-time":"2010-04-23T00:00:00Z","timestamp":1271980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> We report on a series of 92 surgical procedures (90 patients). It includes 35 orthopaedic procedures (33 patients) and 57 non\u2010orthopaedic procedures (57 patients). The orthopaedic procedures include 27 radiosynovectomies (minor surgery) and eight major orthopaedic procedures. The non\u2010orthopaedic procedures include 52 minor interventions and five major procedures. The average age of patients was 34\u2003years (range: 8\u201356), and the average follow\u2010up time was 3\u2003years (range: 1\u20136). Of the 92 surgical procedures, 42 were performed with activated prothrombin complex concentrates [factor eight inhibitor bypassing agent (FEIBA)] and 47 with recombinant\u2010activated factor VIIa (rFVIIa; NovoSeven, Novo Nordisk, Bagsvaerd, Denmark). Regarding FEIBA treatment in minor surgery, the initial dose was 100\u2003IU\u2003kg<jats:sup>\u22121<\/jats:sup>. After 6\u2003h, we continued with 50\u2003IU\u2003kg<jats:sup>\u22121<\/jats:sup> every 12\u2003h for at least 4\u2003days (radiosynovectomies). In minor non\u2010orthopaedic procedures, the dose was continued until day 14. In patients who underwent surgery with the haemostatic control achieved by means of rFVIIa, the initial dose of rFVIIa in minor procedures (both orthopaedic and non\u2010orthopaedic) was 90\u2013120\u2003\u03bcg\u2003kg<jats:sup>\u22121<\/jats:sup>. In postoperative days 1\u20135, the dose was 2\u20134\u2003\u00d7\u200390\u2013120\u2003\u03bcg\u2003kg<jats:sup>\u22121<\/jats:sup> q3\u20136\u2003h for 24\u2003h. In major procedures (both orthopaedic and non\u2010orthopaedic), the dose was 120\u2003\u03bcg\u2003kg<jats:sup>\u22121<\/jats:sup> pre\u2010operatively, 120\u2003\u03bcg\u2003kg<jats:sup>\u22121<\/jats:sup> q 3\u2003h day 2\/day 3\u20135, and then 90\u2013120\u2003\u03bcg\u2003kg<jats:sup>\u22121<\/jats:sup> q 6\u2003h until day 14. There were 87 good results, four fair results and one poor result. Our study has shown that haemophilic patients with inhibitors requiring surgery can undergo orthopaedic and non\u2010orthopaedic procedures with a high expectation of success. In other words, surgery (orthopaedic and non\u2010orthopaedic) is now possible in haemophilia patients with inhibitors, leading to an improved quality of life for these patients.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2010.02223.x","type":"journal-article","created":{"date-parts":[[2010,4,23]],"date-time":"2010-04-23T10:51:21Z","timestamp":1272019881000},"page":"84-88","source":"Crossref","is-referenced-by-count":28,"title":["Surgery in haemophilia patients with inhibitors, with special emphasis on orthopaedics: Madrid experience"],"prefix":"10.1111","volume":"16","author":[{"given":"E. C.","family":"RODRIGUEZ\u2010MERCHAN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"JIMENEZ\u2010YUSTE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"GOMEZ\u2010CARDERO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"ALVAREZ\u2010ROMAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"MARTIN\u2010SALCES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"RODRIGUEZ DE LA RUA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,4,23]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1996.tb01346.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V56.6.978.978"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V61.1.36.36"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1990.30790385521.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90259-0"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-7963(93)70126-1"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-3886(98)00026-5"},{"issue":"1","key":"e_1_2_5_9_2","first-page":"S115","article-title":"Clinical experience with activated factor VII: focus on safety","volume":"9","author":"Roberts HR","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"e_1_2_5_10_2","first-page":"141","article-title":"Treatment with a high titer anti\u2010factor VIII antibody by continuous factor VIII administration: report of a case","volume":"62","author":"White GC","year":"1983","journal-title":"Blood"},{"key":"e_1_2_5_11_2","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1001\/archinte.1989.00390060103022","article-title":"The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII","volume":"149","author":"A Multicenter US experience","year":"1989","journal-title":"Arch Intern Med"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830210209"},{"issue":"1","key":"e_1_2_5_13_2","first-page":"10","article-title":"Use of porcine factor VIII for surgical procedures in haemophilia A patients with inhibitors","volume":"30","author":"Lozier JN","year":"1993","journal-title":"Semin Hematol"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(83)80032-8"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00803.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01520.x"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00938.x"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2010.02223.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2010.02223.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T20:15:45Z","timestamp":1697314545000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2010.02223.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,23]]},"references-count":16,"journal-issue":{"issue":"102","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1111\/j.1365-2516.2010.02223.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2010.02223.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,23]]}}}